PT - JOURNAL ARTICLE AU - Wagstaffe, Helen R. AU - Thwaites, Ryan S. AU - Reynaldi, Arnold AU - Sidhu, Jasmin K. AU - McKendry, Richard AU - Ascough, Stephanie AU - Papargyris, Loukas AU - Collins, Ashley M. AU - Xu, Jiayun AU - Lemm, Nana-Marie AU - Siggins, Matthew K. AU - Chain, Benny M. AU - Killingley, Ben AU - Kalinova, Mariya AU - Mann, Alex AU - Catchpole, Andrew AU - Davenport, Miles P. AU - Openshaw, Peter J.M. AU - Chiu, Christopher TI - Mucosal and Systemic Immune Correlates of Viral Control following SARS-CoV-2 Infection Challenge in Seronegative Adults AID - 10.1101/2023.07.21.23292994 DP - 2023 Jan 01 TA - medRxiv PG - 2023.07.21.23292994 4099 - http://medrxiv.org/content/early/2023/07/23/2023.07.21.23292994.short 4100 - http://medrxiv.org/content/early/2023/07/23/2023.07.21.23292994.full AB - Human infection challenge permits characterisation of the associated immune response in unparalleled depth, enabling evaluation of early pre-symptomatic immune changes and the dynamic immune factors important for viral clearance. Here, 34 healthy young adult volunteers, seronegative to SARS-CoV-2, were inoculated with a D614G-containing pre-Alpha SARS-CoV-2 strain. Nasal and systemic soluble mediator and antibody responses, and peripheral blood T cell and B cell responses were measured by MesoScale Discovery and flow cytometry just before and up to 1 year after intra-nasal inoculation. In the 18 (53%) participants who became infected, both nasal and systemic mediator responses were dominated by interferons (IFN) but with divergent kinetics. T cell activation and proliferation in blood peaked at day 10 in CD4+ T cells and day 14 in CD8+ T cells, returning to baseline by day 28. Following infection, antigen-specific T cells were largely CD38+Ki67+ and displayed central and effector memory phenotypes. T cells contracted after viral clearance with expanded antigen-specific memory T cell populations persisting past day 28. Both mucosal and systemic antibodies became detectable around day 10 but nasal antibodies plateaued after day 14 while circulating antibodies continued to rise. Using piecewise linear regression modelling, viral load related closely to the induction of type I IFN responses, moreover, CD8+ T cell responses and early IgA responses were strongly associated with viral clearance. Detailed analysis of innate and adaptive immune responses to primary SARS-CoV-2 infection following human challenge thus revealed the relationship between immune kinetics and viral load as factors associated with resolution of infection.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialClinicalTrials.gov identifier NCT04865237Funding StatementThis study was funded by the UK Vaccine Taskforce of the Department of Business, Energy and Industrial Strategy of Her Majestys Government (BEIS) and the Wellcome Trust (grant no. 224530/Z/21/Z).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval for this work was given by the UK Health Research Authoritys Ad Hoc Specialist Ethics Committee (references 20/UK/2001 and 20/UK/0002).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.